UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41641

SHL TELEMEDICINE LTD.

(Translation of registrant's name into English)

90 Yigal Alon Street Tel Aviv 67891, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

EXPLANATORY NOTE

On November 20, 2025, SHL Telemedicine Ltd. issued a press release titled "SHL's shareholders confirm increase of share capital", a copy of which is furnished herewith as Exhibit 99.1, and which is incorporated by reference herein.

EXHIBIT INDEX

Exhibit Description

99.1 Press release, dated November 20, 2025, titled "SHL's shareholders confirm increase of share capital"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SHL TELEMEDICINE LTD.

By: /s/ Lior Haalman

Lior Haalman Chief Financial Officer

November 20, 2025



Press release

SHL's shareholders confirm increase of share capital

Tel Aviv / Zurich, November 20, 2025 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, informed that its Special General Meeting of the Shareholders today has confirmed the increase of the Company's authorized share capital from NIS 250,000, divided into 25,000,000 ordinary shares with a nominal value of NIS 0.01 each, to NIS 1,000,000, divided into 100,000,000 ordinary shares with a nominal value of NIS 0.01 each, and the corresponding amendment to the Articles of Association. This is a requirement for the intended capital raising by way of a rights offering.

With the resolution to increase the authorized capital of the Company, the current number of 16,392,754 issued shares will not change. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. Pursuant to SHL's articles of association and Israeli law, the unissued shares are under the sole control of the Board of Directors of SHL who has the authority to issue new shares.

For further information, please contact:

Fabienne Farner, IRF, Phone: +41 43 244 81 42, farner@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

SHL Telemodicine so Yigal Alon St. Tel-Aviv erestaz, Israel T: +972.3.54(22)2 F: +972.3.6242414 www.Shi-Telemedicine.com